semaglutide or tirzepatide injections vs. Semaglutide: Which is Best for Weight Loss? Semaglutide vs Tirzepatide: Key Differences

Regardless of the specific formulation, it is crucial to adhere to the dosing instructions provided by the prescribing healthcare professional and carefully review the medications labeling and patient information

At $15-50 per month, phentermine is accessible to almost everyone

Loukovaara, T

Sahoo et al., 2023)

Key Metrics & Financial Highlights Metric Value Year 1 Revenue $600-800K Year 3 Revenue $10-18M LTV:CAC Ratio 9.8:1 Gross Margin 66% Target Exit Valuation $60-100M (Years 3-4) Initial Capital Required $50-75K MARKET OPPORTUNITY Market Size & Growth Current market: 12 million Americans on GLP-1 medications 2026 projection: 15+ million users Growth rate: 25% annually Patient spend: $900-1,500/month per patient on medication alone Search intent: 50,000+ monthly searches for GLP-1 nutrition solutions Total Addressable Market 12M users 30% willing to pay = 3.6M addressable customers 3.6M $65/month 12 months = $2.8B annual TAM Conservative penetration of 5-10% = $140-280M realistic market Year 1 serviceable market: 1-2% = $28-56M The Problem GLP-1 patients face three critical, interconnected problems: 1

Compounded Injectable Tirzepatide a once-weekly injection format containing a dual GLP-1/GIP receptor agonist